Suppr超能文献

肝细胞癌合并丙型肝炎病毒患者的活体供肝肝移植与尸体供肝肝移植:一项初步的系统综述。

Living Donor Liver Transplantation Versus Deceased Donor Liver Transplantation for Hepatocellular Carcinoma and HCV Patients: An Initial Umbrella Review.

作者信息

Yang Ying, He Yu-Cheng, Cai Yun-Shi, Lv Ying-Hao, Liu Chang, Wu Hong

机构信息

Department of General Surgery, West China Hospital, Sichuan University, Chengdu 610041, China.

Liver Transplant Center, Transplant Center, West China Hospital, Sichuan University, Chengdu 610041, China.

出版信息

J Clin Med. 2025 Apr 28;14(9):3047. doi: 10.3390/jcm14093047.

Abstract

: Living donor liver transplantation (LDLT) has become a widely accepted alternative to deceased donor liver transplantation (DDLT). Nevertheless, the available meta-analyses shed light on a perplexing issue regarding which transplant is better. Therefore, we performed an umbrella review to summarize and evaluate the evidence from current meta-analyses. : Two independent reviewers conducted a search of PubMed, Embase, Web of Science, and the Cochrane Database of Systematic Reviews from inception to 1 June 2024. The methodological quality of each included meta-analysis was evaluated using AMSTAR2 (A Measurement Tool to Assess Systematic Reviews). : The search identified 10 meta-analyses from 486 individual articles, including cohort studies and observational studies. Regrettably, the quality of these meta-analyses ranged from critically low to moderate. Receipt of LDLT offers a survival advantage to the patients with HCC compared with DDLT but with a higher complication rate. However, high-quality studies are required in the future to validate our assertions owing to the low certainty of the evidence. : Despite the complication risks, LDLT remains a cost-effective option without compromising patient and graft survival, especially for HCC patients. Extensive, well-designed studies are essential to validate these conclusions.

摘要

活体供肝肝移植(LDLT)已成为尸体供肝肝移植(DDLT)广泛接受的替代方案。然而,现有的荟萃分析揭示了一个关于哪种移植更好的令人困惑的问题。因此,我们进行了一项综述,以总结和评估当前荟萃分析的证据。

两名独立审稿人对PubMed、Embase、Web of Science和Cochrane系统评价数据库进行了检索,检索时间从建库至2024年6月1日。使用AMSTAR2(一种评估系统评价的测量工具)对每项纳入的荟萃分析的方法学质量进行评估。

检索从486篇个体文章中确定了10项荟萃分析,包括队列研究和观察性研究。遗憾的是,这些荟萃分析的质量从极低到中等不等。与DDLT相比,接受LDLT的肝癌患者具有生存优势,但并发症发生率更高。然而,由于证据的确定性较低,未来需要高质量的研究来验证我们的断言。

尽管存在并发症风险,但LDLT仍然是一种具有成本效益的选择,在不影响患者和移植物存活的情况下,特别是对于肝癌患者。广泛、设计良好的研究对于验证这些结论至关重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cedb/12072381/858770405124/jcm-14-03047-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验